Advances in vaccine adjuvants

@article{Singh1999AdvancesIV,
  title={Advances in vaccine adjuvants},
  author={Manmohan J. Singh and Derek T O'hagan},
  journal={Nature Biotechnology},
  year={1999},
  volume={17},
  pages={1075-1081}
}
Currently, aluminum salts and MF59 are the only vaccine adjuvants approved for human use. With the development of new-generation vaccines (including recombinant subunit and mucosal vaccines) that are less immunogenic, the search for more potent vaccine adjuvants has intensified. Of the novel compounds recently evaluated in human trials, immunostimulatory molecules such as the lipopolysaccharide derived MPL and the saponin derivative QS21 appear most promising, although doubts have been raised… Expand
New adjuvants for parenteral and mucosal vaccines.
TLDR
Recent advances in the understanding of the immune system have led to the identification of new biological targets for vaccine adjuvants, and one can now choose adjuvant able to selectively induce T helper (Th)-1 and/or Th2 responses, according to the vaccine target and the desired immune response. Expand
Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators
TLDR
Current progress in the development of lipid-based vaccine delivery systems is discussed, with a special focus on emulsions, liposomes and immune-stimulating complexes, and their combination with immunostimulatory compounds. Expand
Adjuvant formulations and delivery systems for DNA vaccines.
TLDR
This article focuses on providing the detailed procedure to construct genetic adjuvant plasmids and prepare DNA vaccines formulated with conventional adjuvants, and offers a practical guide for the procedure of intramuscular DNA injection. Expand
Recent advances in self-adjuvanting glycoconjugate vaccines
Compared to traditional vaccines that are formulated into mixtures of an adjuvant and an antigen, a self-adjuvanting vaccine consists of an antigen that is covalently conjugated to a well-definedExpand
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
TLDR
MF59, an oil-in-water emulsion, is currently licensed for use in the elderly as an adjuvant in seasonal influenza vaccines, and its mechanism of action is not fully understood, but enhancement of the interaction between the antigen and the dendritic cell seems to be involved. Expand
2 INITIAL DEVELOPMENT OF ADJUVANTS FOR TOXOID VACCINES : 1920 s – 1940
Since the earliest attempts to raise signifi cant immune responses against nonliving agents, investigators have tried to identify useful additives that can be combined with antigens to enhance immuneExpand
Role and Application of Adjuvants and Delivery Systems in Vaccines
TLDR
For more than 50 years, several novel adjuvants have been evaluated with human vaccines in preclinical and clinical studies and several mechanisms of action for aluminum based adjuvant have been proposed, which are discussed in this chapter. Expand
Cell-Penetrating Peptides: Efficient Vectors for Vaccine Delivery
TLDR
This review describes the different mechanisms of CPP intercellular uptake and various CPP-based vaccine delivery strategies. Expand
Vaccine adjuvants: current challenges and future approaches.
TLDR
A comprehensive discussion is presented of current vaccine adjuvants, their effects on the induction of immune responses, and vaccine adjUVants that have shown promise in recent literature. Expand
Promising particle-based vaccines in cancer therapy
TLDR
It is argued that developmental issues and the lack of reliable preclinical animal models, rather than the lackof innovative vaccine approaches, currently present a major obstacle to rapid and effective vaccine development. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 152 REFERENCES
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
TLDR
Two novel adjuvants that possess significant potential for the development of new vaccines are the MF59 sub-microemulsion and polymeric microparticles and biodegradable polymer poly(lactide-co-glycolide). Expand
Aluminum compounds as vaccine adjuvants.
  • Gupta
  • Chemistry, Medicine
  • Advanced drug delivery reviews
  • 1998
TLDR
Limitations of aluminum adjuvants include local reactions, augmentation of IgE antibody responses, ineffectiveness for some antigens and inability to augment cell-mediated immune responses, especially cytotoxic T-cell responses. Expand
An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
TLDR
The development of an adjuvant formulation able to elicit the formation of protective antibodies and CMI without unacceptable side effects is described. Expand
Immunological adjuvants: a role for liposomes.
TLDR
The use of liposomes is discussed as an alternative safe, versatile, universal adjuvant that can induce humoral- and cell-mediated immunity to antigens when administered parenterally or enterally. Expand
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.
TLDR
Results indicate that the new formulation of recombinant hepatitis B surface antigen combined with a novel adjuvant system, SBAS4--a combination of aluminium salt and monophosphoryl lipid A--is safe, well-tolerated and immunogenic and may promote more rapid protection against hepatitis B infection. Expand
Monophosphoryl Lipid A as an Adjuvant
TLDR
This chapter discusses topics related to the preparation, formulation, and use of MPL® as an adjuvant, a monophosphoryl lipid A preparation derived from the lipopolysaccharide of Salmonella minnesota R595. Expand
Dendritic cells internalize vaccine adjuvant after intramuscular injection.
TLDR
Findings suggest that MF59 interacts with antigen presenting cells at the site of injection and then moves to the draining lymph nodes, where it increases the efficiency of antigen presentation to T cells. Expand
Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.
TLDR
The 200-300 nm diameter emulsion formulation MF59 containing only the low toxicity components squalene, Tween 80 and Span 85 has been shown to enhance titers from 5 to 250 times that achievable with vaccine alone. Expand
QS-21: a water-soluble triterpene glycoside adjuvant.
TLDR
QS-21 has been shown to enhance antibody and cell-mediated immune responses to subunit antigens, as well as DNA vaccines in animal models, and acts as an immunostimulatory adjuvant, eliciting production of immunomodulatory cytokines, and not as an antigen depot. Expand
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
TLDR
It is shown in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with CpG oligodeoxynucleotides and/or CT, and overall, C pG is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as mucosal immune responses (IgA) at local and distant sites. Expand
...
1
2
3
4
5
...